Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SION | CLUSTER | bearish | 7/10 | Two Sionna directors (OrbiMed Advisors and Peter Thompson) sold a combined $26.7M of stock over three days, representing | May 11, 2026 |
| PLSE | CLUSTER | bullish | 7/10 | Two PLSE insiders, including CEO Paul LaViolette and Director Robert Duggan, collectively purchased $13.3M in open-marke | May 11, 2026 |
| ATRA | CLUSTER | mixed | 5/10 | Atara Biotherapeutics saw a mixed insider cluster: 10% owner EcoR1 Capital bought $4.74M worth of shares, while director | May 11, 2026 |
| AVTX | CLUSTER | bearish | 6/10 | Four Avalo Therapeutics insiders, including the CFO, CLO, and CMO, sold a total of $1.53M in open-market stock within da | May 11, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three insiders at United Therapeutics sold a total of $377K in open-market sales over a 7-day window, immediately follow | May 11, 2026 |
| SYRE | CLUSTER | neutral | 3/10 | Four insiders at Spyre Therapeutics, including the CEO, CFO, and CMO, sold a total of $2.92M in open-market sales over a | May 8, 2026 |
| APGE | CLUSTER | neutral | 2/10 | Two C-suite insiders at Apogee Therapeutics sold a combined $377K in stock over a 7-day window, representing less than 0 | May 8, 2026 |
| EXEL | CLUSTER | neutral | 2/10 | Two Exelixis directors sold a combined $3.12M in open-market transactions following a strong Q1 2026 earnings beat (reve | May 8, 2026 |
| RXRX | CLUSTER | neutral | 2/10 | Two directors sold a total of $240K in open-market stock following the Q1 earnings release, but this represents only 0.0 | May 8, 2026 |
| MBX | CLUSTER | neutral | 2/10 | Two top executives (CEO and CMO) sold a total of $25K in open-market sales on May 6, 2026, one day after Q1 earnings bea | May 8, 2026 |
| CORT | CLUSTER | neutral | 3/10 | Corcept Therapeutics' CEO and CDO sold $3.04M in open-market shares within a week of the Q1 earnings release. The trades | May 7, 2026 |
| MPLT | CLUSTER | bearish | 5/10 | MapLight Therapeutics insiders sold a combined $1.3M in open-market sales over a 7-day window, including the CEO, CFO, C | May 6, 2026 |
| TVTX | CLUSTER | bearish | 6/10 | Multiple Travere Therapeutics insiders, including the CEO, CFO, and CMO, sold shares in the days following strong Q1 202 | May 6, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Two insiders sold a total of $239K in ARQT shares, representing only 0.008% of market cap. This is trivial and routine a | May 6, 2026 |
| WST | CLUSTER | neutral | 2/10 | Two officers sold a total of $1.13M in stock post-strong Q1 earnings; nine directors received non-cash stock grants. Sal | May 6, 2026 |
| WST | CLUSTER | neutral | 2/10 | Insider cluster at West Pharmaceutical Services shows $1.13M in open-market sales by two non-C-suite executives shortly | May 6, 2026 |
| IONS | CLUSTER | neutral | 3/10 | Two IONS directors sold approximately $5.1M in stock, which is trivial relative to the company's $12.4B market cap (0.04 | May 6, 2026 |
| WST | CLUSTER | neutral | 2/10 | Two insiders at West Pharmaceutical Services sold a total of $1.13M in shares, representing a trivial 0.005% of market c | May 6, 2026 |
| WST | CLUSTER | neutral | 2/10 | Insider cluster at West Pharmaceutical Services includes two small open-market sales ($1.13M total) and three non-cash d | May 6, 2026 |
| WST | CLUSTER | neutral | 2/10 | Two insiders sold $1.13M worth of WST shares (0.005% of market cap) following strong Q1 earnings. The sales are immateri | May 6, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO and CFO exercised stock options and sold a small number of shares (total ~$558K) coincident with Q1 2026 earnings re | May 6, 2026 |
| SXT | CLUSTER | neutral | 2/10 | Two insiders at Sensient Technologies sold a combined $73K in open-market transactions within a week, a trivial 0.0015% | May 6, 2026 |
| RARE | CLUSTER | neutral | 2/10 | Two Ultragenyx insiders (CFO and Chief Medical Officer) sold a combined $125K in open-market transactions over the past | May 6, 2026 |
| NRIX | CLUSTER | neutral | 3/10 | Three C-suite insiders at Nurix Therapeutics sold a total of $415K in open-market shares over a 7-day window, with the C | May 5, 2026 |
| ACAD | CLUSTER | neutral | 2/10 | Two ACAD insiders (CFO and principal accounting officer) sold small open-market positions totaling ~$105K on May 4, 2026 | May 5, 2026 |
| SRZN | CLUSTER | neutral | 2/10 | CEO Parker Craig and COO Charles Williams sold a combined $219K worth of SRZN shares at ~$33.33 per share. The total val | May 5, 2026 |
| KNSA | CLUSTER | neutral | 4/10 | Kiniksa Pharmaceuticals insiders, including CEO and CMO, sold $5.28M in shares during the week following strong Q1 2026 | May 5, 2026 |
| NUVL | CLUSTER | neutral | 2/10 | Three Nuvalent insiders (CFO, CLO, CDO) sold a total of ~$1.27M in open-market shares over three days, with all sales ti | May 5, 2026 |
| CYTK | CLUSTER | mixed | 4/10 | Multiple CYTK insiders, including CFO and CCO, sold shares totaling $4.53M on the same day as Q1 2026 earnings release s | May 5, 2026 |
| CYTK | CLUSTER | neutral | 3/10 | Two insiders at Cytokinetics sold a combined $2.39M in open-market stock on May 5, 2026, the same day the company report | May 5, 2026 |